Legend Biotech Corp
LEGNHealthcare|Biotechnology|USA
$27.08
-0.32 (-1.17%)
Tangible Book
$5.02
Upcoming Data Readouts (9)
Sep 2026
Est. completion
P1Relapsed B-cell Non-Hodgkin Lymphoma
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957n=42
Mar 2027
Est. completion
Early P1Multiple Myeloma
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625n=36
Jun 2027
Est. completion
P1Relapsed/Refractory B-cell Malignancies
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112n=30
Sep 2027
Est. completion
Early P1Systemic Lupus Erythematosus (SLE)
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
NCT06653556n=34
Dec 2027
Est. completion
P1Gastric Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430n=56
Dec 2027
Est. completion
P1Small Cell Lung Cancer Extensive Stage
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922n=41
Jan 2028
Est. completion
P1Systemic Lupus Erythematosus (SLE)
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272n=38
Feb 2028
Est. completion
NARelapsed/Refractory Multiple Myeloma(MM)
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07100067n=35
Dec 2029
Est. completion
Early P1Relapsed/Refractory Autoimmune Diseases
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075n=36